Brief: Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers
08/12/2023 13:18
Dec 8 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O :
* RIGEL PHARMACEUTICALS AND MD ANDERSON ANNOUNCE STRATEGIC
ALLIANCE TO ADVANCE REZLIDHIA® (OLUTASIDENIB) IN AML AND OTHER
CANCERS
Source text for Eikon: ID:nPn9sWd19a
Further company coverage: RIGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)